[Other] ELOVL6 activity attenuation induces mutant KRAS degradation |
|
This post will be closed automatically in 2026-07-21 01:09
Reward10points
|
20
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
100
Coronary artery calcium in athletes: friend or foe?
20
Maximize Well Integrity During Plug and Abandonment Through Perforate and Wash Operation
20
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
20
A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer
